ReviewJournal of clinical medicine2021
Modulation of Gut Microbiota for the Prevention and Treatment of COVID-19.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Meta-analysis of 16S rRNA microbial data identified alterations of the gut microbiota in COVID-19 patients during the acute and recovery phases.BMC microbiology · 2022Pooled it
- Diagnostic, Prognostic, and Therapeutic Roles of Gut Microbiota in COVID-19: A Comprehensive Systematic Review.Frontiers in cellular and infection microbiology · 2022Pooled it
- Metabolic profiling of healthy vs. syndrome-associated obesity and effects of six-month metformin therapy.Acta diabetologica · 2026 · on this mapTrial
- Alteration of the Gut-Lung Axis After Severe COVID-19 Infection and Modulation Through Probiotics: A Randomized, Controlled Pilot Study.Nutrients · 2024Trial
- Fermentation-driven function enhancement of faba bean (poly)phenols: Bioactivity augmentation and intestinal flora modulation.Food chemistry: X · 2026Article
- Revealing Lactiplantibacillus Plantarum K25 Derived (Z)-18-Octadec-9-Enolide in Modulating Aquaporin-8 in Colorectal Cancer by Bridging the Gut Microbiome and Membrane Biology.Cell biochemistry and biophysics · 2025Article
- Impact of COVID-19 on the Gut Microbiome: A Review.Cureus · 2025Review
- Assessment of upper respiratory and gut bacterial microbiomes during COVID-19 infection in adults: potential aerodigestive transmission.Scientific reports · 2025Article
- Severe alcohol use and COVID-19: implications for physical and mental health.Frontiers in psychiatry · 2025Review
- Article
- The F/B ratio as a biomarker for inflammation in COVID-19 and T2D: Impact of metformin.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Article
- Intestinal barrier dysfunction as a key driver of severe COVID-19.World journal of virology · 2023Review
- Gut microbiome therapeutic modulation to alleviate drug-induced hepatic damage in COVID-19 patients.World journal of gastroenterology · 2023Review
- Molecular Accounting and Profiling of Human Respiratory Microbial Communities: Toward Precision Medicine by Targeting the Respiratory Microbiome for Disease Diagnosis and Treatment.International journal of molecular sciences · 2023Review
- Exploring the Protective Effect of Food Drugs against Viral Diseases: Interaction of Functional Food Ingredients and SARS-CoV-2, Influenza Virus, and HSV.Life (Basel, Switzerland) · 2023Review
- The impact of infection with COVID-19 on the respiratory microbiome: A narrative review.Virulence · 2022Review
- Gastrointestinal Involvement in SARS-CoV-2 Infection.Viruses · 2022Review
- Microbiota in health and diseases.Signal transduction and targeted therapy · 2022Review
- Awareness, Knowledge, and Interest about Prebiotics-A Study among Romanian Consumers.International journal of environmental research and public health · 2022Article
- Phage therapy in the Covid-19 era: Advantages over antibiotics.Current research in microbial sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota is well known to exert multiple benefits on human health including protection from disease causing pathobiont microbes. It has been recognized that healthy intestinal microbiota is of great importance in the pathogenesis of COVID-19. Gut dysbiosis caused by various reasons is associated with severe COVID-19. Therefore, the modulation of gut microbiota and supplementation of commensal bacterial metabolites could reduce the severity of COVID-19. Many approaches have been studied to improve gut microbiota in COVID-19 including probiotics, bacterial metabolites, and prebiotics, as well as nutraceuticals and trace elements. So far, 19 clinical trials for testing the efficacy of probiotics and synbiotics in COVID-19 prevention and treatment are ongoing. In this narrative review, we summarize the effects of various approaches on the prevention and treatment of COVID-19 and discuss associated mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.